Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

Abstract Background Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma. Although durable remissions can be achieved in more than half of these patients, DLBCL remains a significant clinical challenge, with approximately 30% of patients not being cured. BCR-associated kinases (...

Full description

Bibliographic Details
Main Authors: Yizi He, Jiao Li, Ning Ding, Xiaogan Wang, Lijuan Deng, Yan Xie, Zhitao Ying, Weiping Liu, Lingyan Ping, Chen Zhang, Yuqin Song, Jun Zhu
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Diffuse large B cell lymphoma
PKCβ inhibitor
BTK inhibitor
Targeted therapy
Drug combination
Online Access:http://link.springer.com/article/10.1186/s13046-019-1076-4

Internet

http://link.springer.com/article/10.1186/s13046-019-1076-4

Similar Items